A better understanding of the differential molecular aspects of OM action in relation to dose, regional distribution of fast and slow cardiac myosin isoforms and ATPase reaction environment may help to understand the disappointing results of clinical trials testing OM as inotropic support in systolic heart failure compared with currently available inotropic drugs that alter the Ca2+ signalling cascade [27]. The gene discussed is DNAH8; the disease is systolic heart failure.